(redirected from Ampyra)
Also found in: Wikipedia.


(dal-fam-pri-deen) ,


(trade name),


(trade name)


Therapeutic: anti multiple sclerosis agents
Pharmacologic: potassium channel blockers
Pregnancy Category: C


Treatment of mutiple sclerosis, to improve walking speed.


Acts as a potassium channel blocker, which may increase conduction of action potentials.

Therapeutic effects

Increased walking speed in patients with multiple sclerosis.


Absorption: Rapidly and completely absorbed (96%).
Distribution: Unknown.
Metabolism and Excretion: 96% eliminated in urine, 0.5% in feces.
Half-life: 5.2–6.5 hr.

Time/action profile (improvement in walking speed)

POunk3–4 hr24 hr


Contraindicated in: HypersensitivityHistory of seizures;Moderate/severe renal impairment (CCr ≤50 mL/min)(↑ risk of seizures); Lactation: Avoid use.
Use Cautiously in: Mild renal impairment (CCr 51–80 mL/min) (↑ risk of seizures) Geriatric: Consider age-related ↓ in renal function; Obstetric: Use only if potential benefit justifies potential risk to fetus; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • seizures (life-threatening)
  • dizziness
  • headache
  • insomnia
  • weakness

Ear, Eye, Nose, Throat

  • nasopharyngitis
  • pharyngolaryngeal pain


  • constipation
  • dyspepsia
  • nausea


  • urinary tract infection


  • back pain


  • balance disorder
  • multiple sclerosis relapse
  • paresthesia


  • anaphylaxis (life-threatening)


Drug-Drug interaction

None noted.


Oral (Adults) 10 mg twice daily.


Extended-release tablets: 10 mg

Nursing implications

Nursing assessment

  • Assess walking speed in patients with multiple sclerosis prior to and periodically during therapy.
  • Monitor for seizures during therapy, risk increases with increased dose. If seizure occurs, discontinue therapy.
  • Monitor for signs and symptoms of anaphylaxis (dyspnea, wheezing, urticaria, angioedema of the throat or tongue) during therapy.
  • Lab Test Considerations: Monitor creatinine clearance prior to and at least yearly during therapy; renal impairment may require dose reduction or discontinuation.

Potential Nursing Diagnoses

Impaired walking (Indications)


  • Administer tablets twice daily approximately 12 hr apart without regard to food. Administer tablets whole; do not break, crush, chew, or dissolve.

Patient/Family Teaching

  • Instruct patient to take dalfampridine as directed, with approximately 12 hrs between tablets. If a dose is missed, omit and take next scheduled dose on time; do not double doses. May increase risk of seizures. Advise patient to read Medication Guide prior to beginning therapy and with each Rx refill; new information may be available.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • If a seizure or signs or symptoms of anaphylaxis occur, advise patient to notify health care professional immediately, to discontinue dalfampridine, and to report the event to Acorda (manufacturer) at 1-800-367-5109.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

  • Improved walking and increased walking speed in patients with multiple sclerosis.
References in periodicals archive ?
The most common adverse events for AMPYRA in MS patients were urinary tract infection, trouble sleeping, dizziness, headache, nausea, weakness, back pain, and problems with balance.
Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP).
In the first study, paid and rejected Ampyra pharmacy claims were analyzed among commercially insured, continuously enrolled patients during the six-month study period within the 807,801 members who were exposed to the PA and the 257,414 members who were not.
patent application covering the use of AMPYRA in improving walking in people with MS.
Two-year data from more than 62,400 people with multiple sclerosis highlight AMPYRA safety profile
Acorda Therapeutics' Ampyra, Allergan's Botox, and Avanir Pharmaceuticals' Nuedexta make up the crop of new niche agents in the United States indicated specifically for the treatment of individual symptoms that commonly occur in patients with this chronic disease.
A: Ampyra, which was approved by the Food and Drug Administration (FDA) in 2010, is a pill you take twice daily that's been demonstrated to improve walking in people with MS.
AMPYRA is marketed outside the United States as FAMPYRA([R]) (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms 6.
The sustained-release formulation of the potassium channel blocker dalfampridine, marketed as Ampyra by Acorda Therapeutics, was approved in January 2010 to improve walking in people with multiple sclerosis, at a dose of 10 mg twice a day.
Dalfampridine will be marketed as Ampyra by Acorda Therapeutics.
The treatment, called Ampyra, doesn't change the course of the disease.